RxDoctor Payments Data

Molly Peck

Acute Care · Covington, LANPI 1548849680

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,072 of the $3,609 with a category attached, or 85.1%. 22 manufacturers reported payments, led by Boston Scientific at 34.3% of the total. 2025 is the largest year on record at $2,383, 5.3 times the $447 reported in 2023.

$3,609in general payments, 2019–2025

Across 91 payments — averaging $39.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Edwards Lifesciences$341
  • Medtronic$294
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$277
  • AstraZeneca$235
  • Novartis$198
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$53715%
  • Food & beverage$3,07285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,609 in reported general payments places this provider in the 85th percentile of 248 acute care providers in Louisiana.

See all acute care providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,532
Medicare patients
149
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$110,465
Repatha SureclickEvolocumab50$38,209
EntrestoSacubitril/Valsartan37$29,415
Praluent PenAlirocumab14$9,135
Metoprolol Succinate187$2,188
Atorvastatin Calcium126$1,096
Valsartan51$996
Amlodipine Besylate132$871
ClopidogrelClopidogrel Bisulfate101$869
Amiodarone Hcl36$699
Carvedilol76$608
Rosuvastatin Calcium46$493
Ezetimibe47$463
Irbesartan33$427
Olmesartan Medoxomil27$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$110,465133 claims
NovartisEntresto$198$29,41537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 acute care providers in Louisiana.

Other acute care in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →